Discussing Gilead’s Trodelvy for the treatment of HR+/HER2- Metastatic Breast Cancer, Following EMA Approval; PDUFA due February

Scheduled for:Feb 27, 2023 7:00 PM EDT

Call Duration:30 minutes

Desired Expert

An oncologist with experience in treating HR+/HER2- Metastatic Breast Cancer.

Interview Goal

Getting an informed look on Trodelvy for the treatment of HR+/HER2- Metastatic Breast Cancersyndrome.

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.